ES2239527A1 - Topic herpes Zoster treatment composition comprises milk whey mixed with white clay and dissolved in distilled water - Google Patents

Topic herpes Zoster treatment composition comprises milk whey mixed with white clay and dissolved in distilled water

Info

Publication number
ES2239527A1
ES2239527A1 ES200400040A ES200400040A ES2239527A1 ES 2239527 A1 ES2239527 A1 ES 2239527A1 ES 200400040 A ES200400040 A ES 200400040A ES 200400040 A ES200400040 A ES 200400040A ES 2239527 A1 ES2239527 A1 ES 2239527A1
Authority
ES
Spain
Prior art keywords
herpes zoster
distilled water
white clay
topic
dissolved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200400040A
Other languages
Spanish (es)
Other versions
ES2239527B1 (en
Inventor
M. Cruz Fernandez Gonzalez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to ES200400040A priority Critical patent/ES2239527B1/en
Publication of ES2239527A1 publication Critical patent/ES2239527A1/en
Application granted granted Critical
Publication of ES2239527B1 publication Critical patent/ES2239527B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The topic Herpes Zoster treatment composition has a mixture of 17 grams of milk whey mixed with 10 grams of white clay. The mixture is dissolved in 100 milliliters of distilled water via a homogenizer, and incorporated in a phial for subsequent administration.

Description

Composición farmacológica de uso tópico para el tratamiento del Herpes Zoster.Topical pharmacological composition for Herpes Zoster treatment.

Objeto de la invenciónObject of the invention

La presente memoria descriptiva se refiere a una solicitud de una Patente de Invención correspondiente a una composición farmacológica de uso tópico para el tratamiento del Herpes Zoster, que configurada a partir de una mezcla de ácido láctico con arcilla blanca e incorporada sobre una gasa o un algodón es aplicada sobre la superficie afectada, consigue reducir el dolor de forma instantánea y posteriormente seca las vesículas de forma prácticamente inmediata.The present specification refers to a application for an Invention Patent corresponding to a topical pharmacological composition for the treatment of Herpes Zoster, which configured from a mixture of acid lactic with white clay and incorporated on a gauze or a cotton is applied on the affected surface, it reduces pain instantly and subsequently dries the vesicles of practically immediately.

Campo de la invenciónField of the Invention

Esta invención tiene su aplicación dentro de la industria dedicada a la fabricación de composiciones farmacológicas de uso medicamentario.This invention has its application within the industry dedicated to the manufacture of pharmacological compositions of medicinal use.

Antecedentes de la invenciónBackground of the invention

El solicitante desconoce la existencia en la actualidad de una invención que presente características similares a las que se describen en esta memoria.The applicant is unaware of the existence in the topicality of an invention that has similar characteristics to those described herein.

Descripción de la invenciónDescription of the invention

La composición farmacológica de uso tópico para el tratamiento del Herpes Zoster que la invención propone, reduce de forma instantánea el dolor o molestias provocadas por el Herpes Zoster, y a la vez logrando secar las vesículas de forma prácticamente inmediata.The topical pharmacological composition for Herpes Zoster treatment proposed by the invention reduces Instantly the pain or discomfort caused by Herpes Zoster, and at the same time managing to dry the vesicles so practically immediate

De forma más concreta, la composición farmacológica de uso tópico para el tratamiento del Herpes Zoster objeto de la invención, está constituida a partir de un compuesto de ácido láctico mezclado con una cucharada de arcilla blanca, provocándose la mezcla mediante un elemento capacitado para provocar su agitación y obtener una total homogeneización, introduciéndose la composición en un recipiente desde el cual será aplicado sobre una pieza de materia textil y/o algodón para su posterior incorporación de forma superficial y de uso tópico sobre la superficie afectada por el Herpes Zoster.More specifically, the composition topical drug for the treatment of Herpes Zoster object of the invention, is constituted from a compound of lactic acid mixed with a tablespoon of white clay, causing the mixture by means of an element capable of cause agitation and obtain total homogenization, introducing the composition into a container from which it will be applied on a piece of textile and / or cotton for subsequent incorporation of superficial form and topical use on the surface affected by Herpes Zoster.

Debe indicarse que el ácido láctico está configurado como suero de leche y con la colaboración de la arcilla blanca, se disolverán en una proporción adecuada de agua destilada.It should be noted that lactic acid is configured as whey and with the collaboration of clay white, they will dissolve in an adequate proportion of water distilled

Realización preferente de la invenciónPreferred Embodiment of the Invention

La composición farmacológica de uso tópico para el tratamiento del Herpes Zoster que se preconiza, está constituida a partir de 17 gramos de suero de leche, así como de 10 gramos de arcilla blanca, productos que serán incorporados en el interior de un recipiente contenedor de agua destilada, donde serán homogeneizados, empleándose las cantidades citadas anteriormente para su mezcla proporcionar con 10 mililitros de agua destilada.The topical pharmacological composition for the treatment of Herpes Zoster that is recommended is constituted from 17 grams of whey, as well as 10 grams of white clay, products that will be incorporated inside a container containing distilled water, where they will be homogenized, using the amounts mentioned above for your mixture provide with 10 milliliters of water distilled

Una vez realizada la disolución de los ingredientes e incorporados en un vial, se aplicará la mezcla obtenida constitutiva de la composición con una gasa de algodón sobre la zona afectada, preferentemente tres veces al día durante 3 ó 4 días.Once the dissolution of the ingredients and incorporated into a vial, the mixture will be applied obtained constitutive of the composition with a cotton gauze over the affected area, preferably three times a day for 3 or 4 days

Debe indicarse que la zona afectada por la lesión provocada por el Herpes Zoster no debe mojarse durante el tratamiento.It should be noted that the area affected by the injury caused by Herpes Zoster should not get wet during treatment.

Claims (1)

1. Composición farmacológica de uso tópico para el tratamiento del Herpes Zoster, caracterizada por estar constituida a partir de la mezcla proporcional de suero de leche en una cantidad de 17 gramos, a la que se añade arcilla blanca en una cantidad de 10 gramos, en el interior de un homogeneizador conteniendo 100 mililitros de agua destilada en cantidad proporciona a los ingredientes citados, incorporándose posteriormente la mezcla realizada en un vial.1. Topical pharmacological composition for the treatment of Herpes Zoster, characterized by being constituted from the proportional mixture of whey in an amount of 17 grams, to which white clay is added in an amount of 10 grams, in The interior of a homogenizer containing 100 milliliters of distilled water in quantity provides the aforementioned ingredients, subsequently incorporating the mixture made into a vial.
ES200400040A 2004-03-01 2004-03-01 PHARMACOLOGICAL COMPOSITION OF TOPICAL USE FOR THE TREATMENT OF HERPES ZOSTER. Expired - Fee Related ES2239527B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES200400040A ES2239527B1 (en) 2004-03-01 2004-03-01 PHARMACOLOGICAL COMPOSITION OF TOPICAL USE FOR THE TREATMENT OF HERPES ZOSTER.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200400040A ES2239527B1 (en) 2004-03-01 2004-03-01 PHARMACOLOGICAL COMPOSITION OF TOPICAL USE FOR THE TREATMENT OF HERPES ZOSTER.

Publications (2)

Publication Number Publication Date
ES2239527A1 true ES2239527A1 (en) 2005-09-16
ES2239527B1 ES2239527B1 (en) 2006-11-16

Family

ID=35004484

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200400040A Expired - Fee Related ES2239527B1 (en) 2004-03-01 2004-03-01 PHARMACOLOGICAL COMPOSITION OF TOPICAL USE FOR THE TREATMENT OF HERPES ZOSTER.

Country Status (1)

Country Link
ES (1) ES2239527B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018185690A1 (en) 2017-04-06 2018-10-11 Davide Palusci Lipstick for treating herpes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002131A1 (en) * 1992-07-17 1994-02-03 Glyzinc Pharmaceuticals Limited Treatment of herpetic diseases
US6261574B1 (en) * 1997-08-05 2001-07-17 Jeremiah Costello Cream formulation for topical application
ES2192456A1 (en) * 2001-01-03 2003-10-01 Berlin Chemie Ag Once-a-day pharmaceutical composition comprising brivudine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002131A1 (en) * 1992-07-17 1994-02-03 Glyzinc Pharmaceuticals Limited Treatment of herpetic diseases
US6261574B1 (en) * 1997-08-05 2001-07-17 Jeremiah Costello Cream formulation for topical application
ES2192456A1 (en) * 2001-01-03 2003-10-01 Berlin Chemie Ag Once-a-day pharmaceutical composition comprising brivudine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018185690A1 (en) 2017-04-06 2018-10-11 Davide Palusci Lipstick for treating herpes

Also Published As

Publication number Publication date
ES2239527B1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
ES2300027T3 (en) LIQUID PREPARATION FOR VETERINARY MEDICINE, PROCEDURE FOR ITS PRODUCTION AND USE.
AR053680A1 (en) COMPOSITION
JP2019513799A (en) Compositions for the topical application of compounds
BRPI0820520B8 (en) process for the manufacture of chewable dosage forms for the release of drugs and their products
BRPI0416370A (en) controlled release delivery system for nasal applications
BRPI0611400B8 (en) Muco-adhesive xyloglycan-containing formulations useful in medical devices and pharmaceutical formulations
AR082579A2 (en) A PHARMACEUTICAL COMPOSITION SPONTANEALLY AVAILABLE FOR ORAL ADMINISTRATION, USE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER, METHOD FOR INCREASING BIODISPONIBILITY LEVELS OR REDUCING ITS VARIABILITY
ES2457519T3 (en) Water-based pasta containing diclofenac sodium
ES2239527B1 (en) PHARMACOLOGICAL COMPOSITION OF TOPICAL USE FOR THE TREATMENT OF HERPES ZOSTER.
ATE480229T1 (en) ORAL PHARMACEUTICAL COMPOSITION FOR TREATING A COX-2-MEDIATED DISEASE
CN104027279A (en) Antibiosis wet tissue with chamomile smell
RU2604576C1 (en) Pharmaceutical composition for treating infectious-inflammatory diseases of local application and method of its production and application
RU2423989C2 (en) Agent for treating dugs
ATE516015T1 (en) GALENIC FORM FOR ORAL TRANSMUCOSAL DELIVERY OF TRIPTANES
RU2381810C1 (en) Wound healing gel balm
AR093275A1 (en) A PHARMACEUTICAL COMPOSITION SOLUBLE IN WATER THAT INCLUDES AT LEAST A THERAPEUTICALLY ACTIVE SUBSTANCE OF HYDROPHOBIC CHARACTERISTICS AND AT LEAST A SELECTED COMPOSITE BETWEEN THE SYMPHOGLIOPHYMPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYL SOPHYLOPHYLOPHYLOPHYLOSPHYLOPHYLOPHYLOPHYL SINGLE WATER SOLUBLE COMPOSITION IN A WATER SOLUBLE PHARMACEUTICAL COMPOSITION THAT INCLUDES AT LEAST A THERAPEUTICALLY ACTIVE SUBSTANCE OF HYDROPHOBIC CHARACTERISTICS AND AT LEAST A SELECTED COMPOSITE
CN1863529A (en) Topical compositions comprising telmesteine for treating dermatological disorders
WO2016063265A2 (en) Topical formulation for treating skin or mucosal infections, preparation method and uses thereof
ES2296279T3 (en) ANTIPHLOGISTIC AND ANALGESIC COMPOUND FOR TOPICAL USE ON AN AREA OF THE ANIMAL LOCOMOTIVE SYSTEM.
ES2231007A1 (en) Psoriasis treatment cream comprises hydrophilic ointment, urea, salicylic acid and e.g. ammonium lactate
BR102015029617A2 (en) ozonated extra virgin olive oil formulation manufacturing process, preferably organic and product obtained
ITPI20000026A1 (en) SCENTED DISINFECTANT TABLET
RU2560686C2 (en) Pharmaceutical composition for treating herpetic infections
TH75863A (en) A ready-made potion for topical use that contains ambroxol.
ES2238937B2 (en) Liquid natural general purpose infection inhibitor comprises mineral water, alcohol and vegetable matter in a specific mix

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20050916

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2239527B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180809